ロード中...
Upregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus
Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second‐line therapeutic option for hormone therapy‐resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease. Cellular inhibitor of protein phosphatase 2A (CIP2A...
保存先:
| 出版年: | FEBS Open Bio |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7530388/ https://ncbi.nlm.nih.gov/pubmed/32810922 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.12956 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|